ContextVision

CONTEXTVISION AB
SECOND QUARTER 2018

Q2 HIGHLIGHTS

- Stable quarterly sales
- Launch of product concept within digital pathology
- Installation of early product prototype

Q2 FINANCIAL DATA

- Sales of 21.9 MSEK (22.7)
- Operating result of -1.2 MSEK (0.2) and operating margin of -5.4% (0.7%)
- Earnings per share of -0.2 (0.0) SEK

PROGRESS WITHIN DIGITAL PATHOLOGY MAKING CONTEXTVISION EARLY MARKET LEADER

ANITA TOLLSTADIUS, THE COMPANY'S CEO COMMENTED:

The second quarter was signified by good, stable sales after the best Q1 sales in company history, and progress toward the digital pathology market. Sales ended at 21.9 MSEK, compared to 22.7 MSEK in the same period last year. However, increased focus on R&D and pre-marketing activities gave a lower result compared to the same quarter last year (-1.2 MSEK), in full accordance with the long-term strategy.

We have significantly broadened our network and further developed partnerships to provide more collaborations and unique, high quality data sets, which gives us the opportunity to take an early leading position in the market within digital pathology based on AI technology. As a consequence, we have postponed the formal market introduction of our first product to next year, but believe these new partnerships will benefit our overall performance, as we have a stronger platform for a broader product portfolio as well as for marketing and sales in the short term.

The product concept, for the first product for prostate cancer, was launched at the European Congress on Digital Pathology (ECPD) in Helsinki in June, where ContextVision exhibited. The product concept was very well received, generating a lot of interest among attendees. During the congress, we also presented our unique method for generating high quality data for training. This method, MasterAnnotation™, is a unique, patent-filed annotation method developed by ContextVision. Highly relevant data can thereby be used for consistent and specific training of algorithms, a prerequisite for developing robust products.

During the second quarter, again, we proved our skills in deep learning. Following the submission in May, we placed second in the renowned international competition on automated image analysis called the Camelyon Challenge, beating both highly reputable academic teams and research groups from large companies. The competition was initially held last year, but has since opened for resubmissions.

As a result of our external activities and networking, we have started to be recognized as a player within digital pathology with a highly-skilled team within artificial intelligence.

For example, during the second quarter, we have further developed our collaboration with our academic partners at Uppsala University and Uppsala Hospital. Together, we were awarded a grant from Sweden's innovation agency, Vinnova, to continue a research program on lung cancer within digital pathology research. Through this collaboration, we will be able to use a unique set of data for training algorithms in our deep learning network and thereby we will be able to develop highly specific algorithms. Based on this we intend to develop decision support tools that increase the speed and accuracy of the challenging analysis of tissue samples.

In addition, during the second quarter we have established a new collaboration with a research team in Sweden regarding colon cancer research with a focus on lymph node metastases and classification of colon polyps. This provides us with unique training data based on well documented patient data to which deep learning and artificial intelligence will be applied.

We have reached a key milestone in the development of this product. In June, we made a first on-site installation of an early prototype of INIFY™ Prostate, with the potential to facilitate and significantly speed up prostate cancer diagnosis based on digitalized H&E stained biopsy samples. The installation was made through the full integration with the Hospital's Laboratory Information System at the pathology department at Ospedale Cannizzaro in Catania, Italy. This is a fully-digitalized laboratory and will serve as a test center to provide feedback to the project and ensure smooth integration of the product into the clinical workflow. A close dialogue with this highly skilled and experienced team will allow us to optimize the product's performance.

Our ambitious and pioneering R&D strategies, and our external networking during the second quarter, have without any doubt put the company in a very exciting position for future growth.

SECOND QUARTER 2018

OPERATING SEGMENTS

- From January 2018 ContextVision reports its sales, costs and results in two separate operating segments; Business Unit Medical Imaging and Business Unit Digital Pathology. This reflects how the board of directors and the management review and measure the results.
- The Business Unit Medical Imaging comprise research, product development and OEM sales within medical imaging. The product portfolio consists of products developed for a variety of modalities, such as Ultrasound, X-ray, MRI, Mammography, CT and iRV.
- The Business Unit Digital Pathology presently includes research and product development of new products for the growing digital pathology market.

NET SALES AND OPERATING PROFIT

NET SALES

- ContextVisions sales in the second quarter 2018 amounted to 21.9 MSEK, compared to 22.7 MSEK in the same quarter 2017.
- All sales in the quarter was generated from the Business Unit Medical Imaging. All sales income is generated outside Sweden and from external sales.
- The currency exchange rates had an average effect on sales of 4,7% during the quarter. There were positive effects from changes in the EUR exchange rate, while the changes in the USD and JPY exchange rates had a slightly negative effect on sales.

OPERATING PROFIT AND MARGIN

- In the second quarter, ContextVisions operating result was -1.2 MSEK (0.2), and the operating margin -5.4% (0.0%).
- Capitalization is recorded as intangible fixed assets only when product development meets certain requirements. Capitalized costs for development of one product (total 1.3 MSEK) have been recorded during the quarter. This is a higher level of capitalization than previous year, when the capitalization in the same quarter was 0.4 MSEK.

CASH-FLOW AND FINANCING

- The cash flow in the second quarter amounted to -3.7 MSEK (-3.1 MSEK).
- Cash amounted to 37.0 MSEK (37.8) at quarter end.
- Equity at quarter end amounted to 54.4 MSEK (58.8) giving an equity ratio of 72.5% (77.9%).

GOVERNMENT GRANT

- ContextVision was awarded an EU grant in 2015, together with its academic partner University of Applied Sciences an Arts Western Switzerland (HES-SO).
- The company's total part of the grant is TEUR 404, and it will be distributed during a three-year period.
- The first part of the grant (0.6 MSEK) was received in Q4 2015, and was recorded as a cost decrease.
- The second part of the grant (1.3 MSEK) was received in Q4 2016, and was recorded as a cost decrease.
- The third part of the grant (1.3 MSEK) was received in Q4 2017, and was recorded as a cost decrease.
- The final part of the grant is expected to be received in Q4 2018, and will then be recorded as a cost decrease.

EMPLOYEES AND MANAGEMENT

- At period end the company had 43 (42) employees of which 22 (22) are dedicated to research and development. 1 employee is located in the USA and 1 in China.

CONTEXTVISION GROUP

- The group consists of ContextVision AB (publ), company registration number 556377-8900 as parent company, and ContextVision Inc Corp registration number 36-4333625 State of Illinois, USA, as a wholly owned subsidiary.

- Operations in the group are conducted primarily in the parent company and consist of research and development, sales, marketing and administrative functions.

RISKS & UNCERTAINTIES

- ContextVision's major risk factors include business risks connected to the general global financial situation, to the level of healthcare investment on different markets, currency exchange risks, the company's ability to recruit and keep qualified employees and the effect of political decisions.
- The company's risk factors are described in more detail in the annual report 2017. The risks and uncertainties have not changed significantly since then.
- This quarterly report provides a fair and true overview of the company's and the Group's activities, position and results, and describes the risks and uncertainties of significance faced by ContextVision and the companies in the Group.

BASIS OF PREPARATION

- The interim condensed consolidated financial statements for the 2:nd quarter ended June 30:th, 2018 have been prepared in accordance with IAS 34 Interim Financial Reporting and recommendation RFR 1 of the Swedish Financial Reporting Board (RFR), and with regards to the Parent Company, RFR 2. The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the Group's annual financial statements as of December 31, 2017. Apart from the changes in accounting principles stated below, there have been no changes in the accounting principles or methods for calculation during the period.

NEW AND CHANGED ACCOUNTING PRINCIPLES

- From 2018 ContextVision reports its sales and costs in two operating segments; Business Unit Medical Imaging and Business Unit Digital Pathology. This reflects how the board of directors and the management reports and measures the activities internally.
- From 2018 the new standards IFRS 9 Financial Instruments and IFRS 15 Revenue from Contracts with Customers is effective. The impact of the new standards, and how ContextVision applies to them is further described in the annual report 2017.
- The impact of the IFRS 15 standard on the Group's revenue for Q2 2018 is 0.0 MSEK. As of June 30th 2018 there are no contract assets or liabilities. The change to the standard does not influence the cash flow.
- IFRS 16 Leases enters into effect on January 1, 2019 and has been adopted by the EU. The company will continue to evaluate the effects of the new standard during 2018.

SUBSEQUENT EVENTS

- No significant events have occurred during the period between period-end and date of issuance of this report.

The Board of Directors of ContextVision AB
Stockholm 2018-08-15

This report has not been reviewed by the company's auditors.

PRESENTATION AND REPORTING DATES

This quarterly report will be published on the company's website on the 16th of August, 2018.

There will be a video presentation released on the 17th of August, at 09.00 CET.

Please follow the link:
http://webtv.nu/contextvisionq22018

Please visit www.contextvision.com for further information, or use shareholderinfo@contextvision.se to send a question directly to management.

REPORTING DATES

Q4 and 12 months 2017	February 22, 2018
Annual report available on company's website	April 5, 2018
Q1 result 2018	April 26, 2018
Annual General Meeting	May 9, 2018
Q2 result 2018	August 16, 2018
Q3 result 2018	October 25, 2018
Q4 and 12 months 2018	February 21, 2019

FOR MORE INFORMATION PLEASE CONTACT:

Anita Tollstadius, CEO
Phone +46 (0)8 750 35 50

CONTEXTVISION FAST FACTS

- ContextVision is a medical technology software company that specializes in image analysis and artificial intelligence.
- ContextVision is the global market leader within image enhancement and is a software partner to leading medical imaging manufacturers all over the world.
- The company is based in Sweden, with local representation in the U.S., Russia, Japan, China and Korea.
- ContextVision is a spin-off from the Image Processing Laboratory at Linköping University, Sweden. The corporate identity was established in 1983 with the first OEM agreement in radiology in 1987.
- The company's share is traded on the Oslo Stock Exchange since 1997, under the ticker COV.

THE COMPANY OFFERS:

- 30 years of successful experience in OEM business.
- Unprecedented image enhancement for ultrasound, X-Ray, MRI, CT, mammography and iRV.
- Long standing corporate commitment to R&D that ensures timely and rewarding upgrade paths.
- Strong customer relationships to ensure their success.
- Expert training in image processing for our customers.
- Compatibility across different image formats and major computer platforms.
- ContextVision's technology enables the company's customers to provide superior digital imaging solutions for hospitals and clinicians. Such solutions promise more rapid and accurate diagnoses, reduced operator eye fatigue, and ultimately, a greater return-on-investment for medical imaging users.

CONSOLIDATED INCOME STATEMENT (SEK 1000)

	Q2 2018	Q2 2017	SIX MONTHS 2018	SIX MONTHS 2017	FULL YEAR 2017
Net sales	21 869	22 744	41 080	40 005	80 512
Total revenues	**21 869**	**22 744**	**41 080**	**40 005**	**80 512**
Goods for resale	-521	-522	-947	-934	-2 235
Other external costs	-8 132	-7 751	-16 334	-14 528	-27 942
Personnel costs	-13 134	-12 950	-25 630	-25 070	-47 429
Depreciation assets	-1 264	-1 359	-2 488	-2 702	-4 878
Operating results	**-1 182**	**161**	**-4 319**	**-3 229**	**-1 972**
Interest income	0	1	0	0	4
Interest cost	-5	-10	-5	-10	-10
Results after financial items	**-1 187**	**152**	**-4 324**	**-3 239**	**-1 978**
Tax	-15	-66	-7	675	272
Net results	**-1 203**	**86**	**-4 331**	**-2 564**	**-1 706**
Earnings per share after tax (SEK)	-0,16	0,01	-0,56	-0,33	-0,22

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (SEK 1000)

	Q2 2018	Q2 2017	SIX MONTHS 2018	SIX MONTHS 2017	FULL YEAR 2017
Effect of currency hedging	-12	-32	-675	18	-229
Translation difference	88	-82	108	-110	-145
Total other comprehensive income	**76**	**-114**	**-567**	**-92**	**-374**
Net result for the period	-1 203	86	-4 331	-2 564	-1 706
Total comprehensive income for the period	**-1 127**	**-28**	**-4 898**	**-2 656**	**-2 080**

FINANCIAL HIGHLIGHTS

	Q2 2018	Q2 2017	SIX MONTHS 2018	SIX MONTHS 2017	FULL YEAR 2017
Earnings per share after tax (SEK) before/after dilution	-0,16	0,01	-0,56	-0,33	-0,22
Average number of shares	7 736 750	7 736 750	7 736 750	7 736 750	7 736 750
Operating margin (per cent)	-5,4	0,7	-10,5	-8,1	-2,5
Solidity (per cent)	72,5	77,9	72,5	77,9	75,1

DEFINITIONS

Earnings per share after tax (Return on equity): Net result for the period as a percentage of the average equity.
Operating margin: Operating income excluding non-recurring items as a percentage of net sales.
Profit margin: Result after financial items as a percentage of net sales.
Solidity (Equity ratio): Equity as a percentage of total assets.

SALES BY REGION (MSEK)

	Q2 2018	Q2 2017	SIX MONTHS 2018	SIX MONTHS 2017	FULL YEAR 2017
Asia	12,1	11,1	21,8	19,6	42,3
Europe	7,6	7,7	14,4	14,5	29,5
USA	2,2	3,9	4,9	5,9	8,7
Total	**21,9**	**22,7**	**41,1**	**40,0**	**80,5**

SALES BY PRODUCT (MSEK)

	Q2 2018	Q2 2017	SIX MONTHS 2018	SIX MONTHS 2017	FULL YEAR 2017
XR	3,0	3,7	5,9	6,1	9,5
US 2D	12,8	12,0	24,2	22,3	48,3
US 3D	4,5	3,8	7,5	6,3	13,2
MR	1,4	2,6	3,0	3,7	6,9
Others (iRV, CT, Mammo)	0,2	0,6	0,5	1,6	2,6
Total	**21,9**	**22,7**	**41,1**	**40,0**	**80,5**

BUSINESS UNITS / OPERATING SEGMENTS (MSEK)

	Q2 2018 BUSINESS UNIT MEDICAL IMAGING	Q2 2017 BUSINESS UNIT MEDICAL IMAGING	Q2 2018 BUSINESS UNIT DIGITAL PATHOLOGY	Q2 2017 BUSINESS UNIT DIGITAL PATHOLOGY	Q2 2018 GROUP TOTAL	Q2 2017 GROUP TOTAL
Net sales	21,9	22,7	-	-	21,9	22,7
Operating expenses	-15,6	-17,9	-7,5	-4,6	-23,1	-22,5
Operating results	6,3	4,8	-7,5	-4,6	-1,2	0,2

CONSOLIDATED BALANCE SHEET (SEK 1000)

	JUNE 30TH, 2018	JUNE 30TH, 2017			FULL YEAR 2017
Intangible fixed assets	10 571	12 707			10 778
Tangible assets	3 681	584			3 742
Other financial assets	653	328			376
Inventories	1 131	654			576
Current receivables	22 007	23 353			23 266
Cash and bank	37 044	37 805			40 327
Total assets	**75 087**	**75 431**			**79 065**
Equity	54 449	58 770			59 346
Deferred taxes	1 112	1 521			1 122
Current liabilities	19 516	15 140			18 597
Total equity and liabilities	**75 087**	**75 431**			**79 065**

CHANGE IN EQUITY (SEK 1000)

	Q2 2018	Q2 2017	SIX MONTHS 2018	SIX MONTHS 2017	FULL YEAR 2017
Opening balance	55 575	58 797	59 346	61 426	61 426
Total comprehensive income for the period	-1 127	-28	-4 898	-2 656	-2 080
Closing balance	**54 449**	**58 770**	**54 449**	**58 770**	**59 346**

CONSOLIDATED STATEMENT OF CASH FLOWS (SEK 1000)

	Q2 2018	Q2 2017	SIX MONTHS 2018	SIX MONTHS 2017	FULL YEAR 2017
Result after financial items	-1 187	152	-4 325	-3 239	-1 978
Depreciation and write-down of assets	1 264	1 491	2 489	2 921	4 878
Unrealized gain/loss on current investments	-12	-32	-675	18	-229
Income tax paid	-407	-3 576	-601	-3 776	-2 358
Cash flow from operating activities before change in working capital	**-343**	**-1 965**	**-3 112**	**-4 076**	**313**
Change in working capital					
Increase (-)/decrease (+) inventories	498	161	-555	-360	-282
Increase (-)/decrease (+) current receivables	-1 357	-2 509	1 642	593	-700
Increase (+)/decrease (-) liabilities	-867	1 591	1 108	-276	2 617
Cash flow from operating activities	**-2 068**	**-2 722**	**-918**	**-4 119**	**1 948**
Investing activities					
Investments in intangible assets	-1 306	-386	-1 971	-815	-1 038
Investments in tangible assets	-315	-29	-394	-167	-3 494
Other financial assets	-	-5	-	-5	-
Cash flow from investing activities	**-1 621**	**-420**	**-2 365**	**-987**	**-4 532**
Financing activities					
Cash flow from financing activities	**0**	**0**	**0**	**0**	**0**
Cash flow for the period	**-3 689**	**-3 142**	**-3 283**	**-5 106**	**-2 584**
Change of liquid assets					
Liquid assets at beginning of period	40 733	40 946	40 327	42 910	42 910
Liquid assets at period end	**37 044**	**37 805**	**37 044**	**37 805**	**40 327**

PARENT COMPANY INCOME STATEMENT (SEK 1000)

	Q2 2018	Q2 2017	SIX MONTHS 2018	SIX MONTHS 2017	FULL YEAR 2017
Net sales	21 869	22 744	41 080	40 005	80 512
Total revenues	**21 869**	**22 744**	**41 080**	**40 005**	**80 512**
Goods for resale	-521	-522	-947	-934	-2 235
Other external costs	-8 756	-8 780	-17 562	-16 452	-31 357
Personnel costs	-12 556	-11 982	-24 483	-23 267	-44 229
Depreciation assets	-1 264	-1 359	-2 488	-2 702	-4 878
Operating results	**-1 228**	**100**	**-4 400**	**-3 350**	**-2 188**
Interest income	-	1	-	-	4
Interest cost	-5	-10	-5	-10	-10
Dividends from group company	-	-	-	-	334
Results after financial items	**-1 233**	**91**	**-4 405**	**-3 360**	**-1 860**
Provision for tax allocation reserve	-	-	-	-	1 650
Tax	-	-45	22	669	-24
Net results	**-1 233**	**47**	**-4 383**	**-2 691**	**-234**
Earnings per share after tax (SEK)	-0,16	0,01	-0,57	-0,35	-0,03

PARENT COMPANY STATEMENT OF COMPREHENSIVE INCOME (SEK 1000)

	Q2 2018	Q2 2017	SIX MONTHS 2018	SIX MONTHS 2017	FULL YEAR 2017
Effect of currency hedging	-12	-31	-675	18	-229
Total other comprehensive income	**-12**	**-31**	**-675**	**18**	**-229**
Net result for the period	-1 233	47	-4 383	-2 691	-234
Total comprehensive income for the period	**-1 245**	**16**	**-5 058**	**-2 673**	**-463**

FINANCIAL HIGHLIGHTS

	Q2 2018	Q2 2017	SIX MONTHS 2018	SIX MONTHS 2017	FULL YEAR 2017
Earnings per share after tax (SEK) before/after dilution	-0,16	0,01	-0,57	-0,35	-0,03
Average number of shares	7 736 750	7 736 750	7 736 750	7 736 750	7 736 750
Operating margin (per cent)	-5,6	0,4	-10,7	-8,4	-2,7
Solidity (per cent)	65,8	69,4	65,8	69,4	68,9

DEFINITIONS

Earnings per share after tax (Return on equity): Net result for the period as a percentage of the average equity.
Operating margin: Operating income excluding non-recurring items as a percentage of net sales.
Profit margin: Result after financial items as a percentage of net sales.
Solidity (Equity ratio): Equity as a percentage of total assets.

SALES BY REGION (MSEK)

	Q2 2018	Q2 2017	SIX MONTHS 2018	SIX MONTHS 2017	FULL YEAR 2017
Asia	12,1	11,1	21,8	19,6	42,3
Europe	7,6	7,7	14,4	14,5	29,5
USA	2,2	3,9	4,9	5,9	8,7
Total	**21,9**	**22,7**	**41,1**	**40,0**	**80,5**

SALES BY PRODUCT (MSEK)

	Q2 2018	Q2 2017	SIX MONTHS 2018	SIX MONTHS 2017	FULL YEAR 2017
XR	3,0	3,7	5,9	6,1	9,5
US 2D	12,8	12,0	24,2	22,3	48,3
US 3D	4,5	3,8	7,5	6,3	13,2
MR	1,4	2,6	3,0	3,7	6,9
Others (iRV, CT, Mammo)	0,2	0,6	0,5	1,6	2,6
Total	**21,9**	**22,7**	**41,1**	**40,0**	**80,5**

PARENT COMPANY BALANCE SHEET (SEK 1000)

	JUNE 30TH 2018	JUNE 30TH 2017			FULL YEAR 2017
Intangible fixed assets	10 571	12 707			10 778
Tangible assets	3 681	584			3 742
Other financial assets	870	545			593
Inventories	1 131	654			576
Current receivables	21 983	23 312			23 240
Cash and bank	36 708	37 448			40 062
Total assets	**74 944**	**75 250**			**78 991**
Equity	49 342	52 190			54 400
Untaxed reserves	5 100	6 786			5 100
Current liabilities	20 502	16 274			19 491
Total equity and liabilities	**74 944**	**75 250**			**78 991**

CHANGE IN EQUITY (SEK 1000)

	Q2 2018	Q2 2017	SIX MONTHS 2018	SIX MONTHS 2017	FULL YEAR 2017
Opening balance	50 586	52 174	54 400	54 862	54 862
Total comprehensive income for the period	-1 245	16	-5 058	-2 673	-463
Closing balance	**49 342**	**52 190**	**49 342**	**52 190**	**54 400**

GLOSSARY

ARTIFICIAL INTELLIGENCE (AI)
Artificial Intelligence is the intelligence exhibited by machines or software.

DEEP LEARNING
Deep learning is the latest very powerful technology within machine learning; machine learning with deep neural networks

DIGITAL PATHOLOGY
Digital pathology refers to the digital images of histopathology samples. The digitalization is achieved by scanning the prepared samples.

GOP® (GENERAL OPERATOR PROCESSOR)
ContextVision's methodology and technology base for image analysis and image enhancement, detecting structures in an image and relating them to their wider context in order to increase visualization accuracy.

GOPICE® (IMAGE CUBICLE ENHANCMENENT)
ContextVision's real-time 3D volumetric image enhancement product, for OEM embedded software.

GOPVIEW® / PLUSVIEW®
The family names for ContextVision's 2D product lines of OEM-embedded software.

HANDHELD ULTRASOUND
A small ultrasound unit that can be held in the hand when performing the examination, e.g. smartphones and tablet-based systems.

IMAGE ANALYSIS
Processing a digital image in order to describe/classify its contents or to extract quantitative measurements.

IMAGE PROCESSING
A generic term used to describe the computation of digital images, typically to enhance or analyze them.

IMAGE ENHANCEMENT
To improve the visual quality of a digital image by increasing the visibility of relevant structures, as in edge/contrast enhancement and the suppression of noise or artifacts.

MACHINE LEARNING
Machine learning is the study of computer algorithms that improve automatically through experience

MAMMOGRAPHY
An X-ray method used to examine the human breast.

MODALITY
A device that generates internal images of the body, such as X-ray, ultrasound, magnetic resonance imaging, and computed tomography.

MRI (MAGNETIC RESONANCE IMAGING)
A non-invasive procedure, generated by variations in strong magnetic fields, that produces a two-dimensional view of an internal organ or structure, especially the brain and spinal cord.

OEM
The acronym for Original Equipment Manufacturer.

REALICE™
REALiCE is a volume enhancement and rendering product package for 3D and 4D fetal volume visualization.

US (ULTRASOUND)
A procedure in which high-energy sound waves are bounced off internal tissues or organs to create echoes. The echo patterns are displayed on the screen of an ultrasound machine, forming sa picture of body tissues called a sonogram.

VOLARVIEW™
ContextVision's image enhancement product for handheld ultrasound units.

XR (X-RAY)
A diagnostic device in which radiation is used to create images for examination of soft and hard tissue, such as muscle and bone.

ContextVision

ContextVision is a medical technology software company that specializes in image analysis and artificial intelligence. ContextVision is the global market leader within image enhancement and is a software partner to leading medical imaging manufacturers all over the world. Its cutting-edge technology helps doctors accurately interpret medical images, a crucial foundation for better diagnosis and treatment.

As an industry pioneer for more than 30 years, ContextVision is significantly investing in R&D to develop new applications of the latest artificial intelligence technologies and expanding into the growing digital pathology market. The release of its first product, supporting the diagnosis of prostate cancer, is planned in the near future.

The company is based in Sweden, with local representation in the U.S., Russia, Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker COV.

FOR MORE INFORMATION, PLEASE VISIT WWW.CONTEXTVISION.COM